RESUMEN
The E3 ubiquitin ligase (E3) WWP1 is an oncogenic factor implicated in the maintenance of different types of epithelial cancers. The role of WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) in haematological neoplasms remains unknown. Acute myeloid leukaemia (AML) is characterized by the expansion of malignant myeloid cells blocked at different stages of differentiation. Here we report that the expression of WWP1 is significantly augmented in a large cohort of primary AML patients and in AML cell lines, compared with haematopoietic cells from healthy donors. We show that WWP1 inactivation severely impairs the growth of primary AML blasts and cell lines in vitro. In vivo, we observed a reduced leukaemogenic potential of WWP1-depleted AML cells upon transplantation into immunocompromised mice. Mechanistically, WWP1 inactivation induces the accumulation of its protein substrate p27Kip1, which ultimately contributes to G0/G1 cell cycle arrest of AML blasts. In addition, WWP1 depletion triggers the autophagy signalling and reduces survival of leukaemic cells. Collectively, our findings provide molecular insights into the anti-cancer potential of WWP1 inhibition, suggesting that this E3 is a promising biomarker and druggable target in AML.
Asunto(s)
Leucemia Mieloide Aguda/metabolismo , Leucemia Mieloide Aguda/patología , Ubiquitina-Proteína Ligasas/metabolismo , Animales , Puntos de Control del Ciclo Celular/fisiología , Diferenciación Celular/fisiología , Línea Celular Tumoral , Proliferación Celular/fisiología , Supervivencia Celular/fisiología , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/metabolismo , Fase G1/fisiología , Regulación Neoplásica de la Expresión Génica/fisiología , Humanos , Ratones , Fase de Descanso del Ciclo Celular/fisiología , Transducción de Señal/fisiología , Células U937 , Ubiquitinación/fisiologíaRESUMEN
It has been shown that individual acute myeloid leukemia (AML) patients are characterized by one of few initiating DNA mutations and 5-10 cooperating mutations not yet defined among hundreds identified by massive sequencing of AML genomes. We report an in vivo insertional-mutagenesis screen for genes cooperating with one AML initiating mutations (PML-RARA, oncogene of acute promyelocytic leukemia, APL), which allowed identification of hundreds of genetic cooperators. The cooperators are mutated at low frequency in APL or AML patients but are always abnormally expressed in a cohort of 182 APLs and AMLs analyzed. These deregulations appear non-randomly distributed and present in all samples, regardless of their associated genomic mutations. Reverse-engineering approaches showed that these cooperators belong to a single transcriptional gene network, enriched in genes mutated in AMLs, where perturbation of single genes modifies expression of others. Their gene-ontology analysis showed enrichment of genes directly involved in cell proliferation control. Therefore, the pool of PML-RARA cooperating mutations appears large and heterogeneous, but functionally equivalent and deregulated in the majority of APLs and AMLs. Our data suggest that the high heterogeneity of DNA mutations in APLs and AMLs can be reduced to patterns of gene expression deregulation of a single 'mutated' gene network.
Asunto(s)
Redes Reguladoras de Genes/genética , Leucemia Mieloide/genética , Mutación , Proteínas de Fusión Oncogénica/genética , Animales , Carcinogénesis/genética , Bases de Datos Genéticas , Humanos , Leucemia Mieloide Aguda , Leucemia Promielocítica Aguda , Ratones , Células 3T3 NIHRESUMEN
Mutations in the Nucleophosmin (NPM1) gene have been recently described to occur in about one-third of acute myeloid leukemias (AML) and represent the most frequent genetic alteration currently known in this subset. These mutations generate an elongated NPM1 protein that localizes aberrantly in the cytoplasm. In analogy with Flt3 alterations, NPM1 mutations are mostly detectable in AML with normal karyotype and their recognition may be relevant to identify distinct response to treatment. Hence, in addition to conventional karyotyping and RT-PCR of fusion genes, combined analysis of both Flt3 and NPM1 mutations will be increasingly relevant in the genetic diagnosis work-up of AML. We developed a multiplex RT-PCR assay followed by capillary electrophoresis to simultaneously analyze NPM1 and Flt3 gene alterations (NFmPCR assay). The assay was validated in leukemic cell RNAs extracted from 38 AML patients, which had been previously characterized for Flt3 status by conventional RT-PCR. Direct sequencing of NPM1 RT-PCR products was carried out in 15 cases to verify results obtained by capillary electrophoresis. Both NPM1 sequencing and conventional RT-PCR Flt3 results showed 100% concordance with the results of the NFmPCR assay. We suggest that this assay may be introduced in routine analysis of genetic alterations in AML.
Asunto(s)
Leucemia Mieloide/genética , Mutación , Proteínas Nucleares/genética , Proteínas Proto-Oncogénicas/genética , Proteínas Tirosina Quinasas Receptoras/genética , Secuencias Repetidas en Tándem , Enfermedad Aguda , Electroforesis Capilar , Humanos , Leucemia Mieloide/diagnóstico , Métodos , Nucleofosmina , ARN Neoplásico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Análisis de Secuencia de ARN , Tirosina Quinasa 3 Similar a fmsRESUMEN
The APL0406 study showed that arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are not inferior to standard ATRA and chemotherapy (CHT) in newly diagnosed, low-intermediaterisk acute promyelocytic leukaemia (APL). We analysed the kinetics of promyelocytic leukaemia-retinoic acid receptor-α (PML-RARα) transcripts by real-time quantitative PCR (RQ-PCR) in bone marrow samples from 184 patients and assessed the prognostic impact of fms-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD) in 159 patients enrolled in this trial in Italy. After induction therapy, the reduction of PML-RARα transcripts was significantly greater in patients receiving ATRA-CHT as compared with those treated with ATRA-ATO (3.4 vs 2.9 logs; P=0.0182). Conversely, at the end of consolidation, a greater log reduction of PML-RARα transcripts was detected in the ATRA-ATO as compared with the ATRA-CHT group (6.3 vs 5.3 logs; P=0.0024). FLT3-ITD mutations had no significant impact on either event-free survival (EFS) or cumulative incidence of relapse in patients receiving ATRA-ATO, whereas a trend for inferior EFS was observed in FLT3-ITD-positive patients receiving ATRA-CHT. Our study shows at the molecular level that ATRA-ATO exerts at least equal and probably superior antileukaemic efficacy compared with ATRA-CHT in low-intermediaterisk APL. The data also suggest that ATRA-ATO may abrogate the negative prognostic impact of FLT3-ITD.
Asunto(s)
Arsenicales/administración & dosificación , Leucemia Promielocítica Aguda/tratamiento farmacológico , Proteínas de Fusión Oncogénica/sangre , Óxidos/administración & dosificación , Tretinoina/administración & dosificación , Tirosina Quinasa 3 Similar a fms/genética , Adolescente , Adulto , Anciano , Trióxido de Arsénico , Arsenicales/uso terapéutico , Supervivencia sin Enfermedad , Femenino , Humanos , Quimioterapia de Inducción/métodos , Italia , Cinética , Leucemia Promielocítica Aguda/genética , Leucemia Promielocítica Aguda/mortalidad , Masculino , Persona de Mediana Edad , Mutación , Óxidos/uso terapéutico , Pronóstico , Tretinoina/uso terapéutico , Adulto JovenAsunto(s)
Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/terapia , Proteínas de Fusión Oncogénica/genética , Factor de Transcripción STAT5/genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Antineoplásicos/farmacología , Trióxido de Arsénico/farmacología , Resistencia a Antineoplásicos , Leucemia Promielocítica Aguda/genética , Mutación , Reacción en Cadena de la Polimerasa/métodos , Proteína de la Leucemia Promielocítica/genética , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Leucemia Promielocítica Aguda/diagnóstico , Leucemia Promielocítica Aguda/tratamiento farmacológico , Masculino , Persona de Mediana Edad , PronósticoRESUMEN
MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, are involved in many complex cellular processes. Several miRNAs are differentially expressed in hematopoietic tissues and play important roles in normal differentiation, but, when aberrantly regulated, contribute to the abnormal proliferation and differentiation of leukemic cells. Recently, we reported that a small subset of miRNAs is differentially expressed in acute promyelocytic leukemia (APL) blasts and is modulated by treatment with all-trans-retinoic acid (ATRA). In particular, PML/RARα-positive blasts from APL patients display lower levels of miRNA let-7c, a member of the let-7 family, than normal promyelocytes and its expression increases after ATRA treatment. In this study, we investigated the effects of let-7c in acute myeloid leukemia (AML) cells. We found that ectopic expression of let-7c promotes granulocytic differentiation of AML cell lines and primary blasts. Moreover, we identified PBX2, a well-known homeodomain protein whose aberrant expression enhances HoxA9-dependent leukemogenesis, as a novel let-7c target that may contribute to the AML phenotype. Together, these studies raise the possibility that perturbation of the let-7c-PBX2 pathway may have a therapeutic value in AML.
Asunto(s)
Diferenciación Celular/genética , Granulocitos/patología , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/patología , MicroARNs/genética , MicroARNs/metabolismo , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica/genética , Proteínas de Homeodominio/genética , Proteínas de Homeodominio/metabolismo , Humanos , Células Mieloides/patología , Fenotipo , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas/metabolismoRESUMEN
Therapy-related acute promyelocytic leukemia (t-APL) has been reported as a late complication of exposure to radiotherapy and/or chemotherapeutic agents targeting DNA topoisomerase II. We have analyzed in t-APL novel gene mutations recently associated with myeloid disorders. Unlike previous reports in acute myeloid leukemia (AML), our results showed neither IDHs nor TET2 mutations in t-APL. However we found an R882H mutation in the DNMT3A gene in a patient with t-APL suggesting a possible role of this alteration in the pathogenesis of t-APL.
Asunto(s)
Leucemia Promielocítica Aguda/etiología , Leucemia Promielocítica Aguda/genética , Adulto , Anciano , Antineoplásicos/efectos adversos , Niño , ADN (Citosina-5-)-Metiltransferasas/genética , ADN Metiltransferasa 3A , Análisis Mutacional de ADN , Proteínas de Unión al ADN/genética , Dioxigenasas , Femenino , Humanos , Isocitrato Deshidrogenasa/genética , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas/genética , Radioterapia/efectos adversos , Adulto Joven , Tirosina Quinasa 3 Similar a fms/genéticaAsunto(s)
Carnitina/análogos & derivados , Ácido Graso Desaturasas/deficiencia , Errores Innatos del Metabolismo Lipídico/dietoterapia , Errores Innatos del Metabolismo Lipídico/diagnóstico , Acil-CoA Deshidrogenasa , Carnitina/sangre , Femenino , Humanos , Lactante , Errores Innatos del Metabolismo Lipídico/sangre , Espectrometría de Masas/métodos , Monitoreo Fisiológico/métodosRESUMEN
MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of critical cell processes such as apoptosis, cell proliferation and differentiation. A small set of miRNAs is differentially expressed in hematopoietic cells and seemingly has an important role in granulopoiesis and lineage differentiation. In this study, we analysed, using a quantitative real-time PCR approach, the expression of 12 granulocytic differentiation signature miRNAs in a cohort of acute promyelocytic leukemia (APL) patients. We found nine miRNAs overexpressed and three miRNAs (miR-107, -342 and let-7c) downregulated in APL blasts as compared with normal promyelocytes differentiated in vitro from CD34+ progenitors. Patients successfully treated with all-trans-retinoic acid (ATRA) and chemotherapy showed downregulation of miR-181b and upregulation of miR-15b, -16, -107, -223, -342 and let-7c. We further investigated whether the APL-associated oncogene, promyelocytic leukemia gene (PML)/retinoic acid receptor alpha (RARalpha), might be involved in the transcriptional repression of miR-107, -342 and let-7c. We found that PML/RARalpha binds the regulatory sequences of the intragenic miR-342 and let-7c. In addition, we observed, in response to ATRA, the release of PML/RARalpha paralleled by their transcriptional activation, together with their host genes, EVL and C21orf34alpha. In conclusion, we show that a small subset of miRNAs is differentially expressed in APL and modulated by ATRA-based treatment.
Asunto(s)
Leucemia Promielocítica Aguda/genética , MicroARNs/análisis , Células Precursoras de Granulocitos/patología , Humanos , Leucemia Promielocítica Aguda/metabolismo , Leucemia Promielocítica Aguda/patología , MicroARNs/genéticaRESUMEN
The treatment of multiple acyl-CoA-dehydrogenase deficiency (MADD) includes a low-fat, low-protein, high-carbohydrate diet, avoiding long fasting periods. However, there is no useful biochemical marker to determine the response to different diets or fasting periods. The aims of this study are to report a patient with MADD, diagnosed through a newborn screening program using tandem mass spectrometry, to assess her response to different feedings, and to evaluate the usefulness of acylcarnitines and FFA to monitor the response to dietary changes. The patient was diagnosed at 6 d. Family history revealed three dead siblings. Five tests were performed, one with breast milk and the subsequent four after giving the patient a bottle of a low-fat, low-protein formula (F), F with glucose polymers (GP), F+GP plus uncooked corn starch (CS), or F+GP+CS preceded by amylase. The results showed that acylcarnitines, FFA, and total nonesterified fatty acids levels were greatly improved at 2 and 4 h on F+GP compared with breast milk. At 6 mo of age, the test with F+CS was repeated to assess the response to a longer fast. The results were similar at 2 and 4 h, but showed a marked increase of acylcarnitines, FFA, and total nonesterified fatty acids at 6 h. The increase of these metabolites could not be avoided by the use of F+GP+CS, but was prevented when amylase was used simultaneously. The patient is currently 3.9 y old and has normal growth and development. We conclude that diagnosis of MADD through a newborn screening program using tandem mass spectrometry is suitable; acylcarnitines and FFA are useful to monitor the response to treatment; and exogenous amylase allows the use of CS in small children with MADD. This therapeutic approach may be an alternative to the use of continuous overnight feedings used for young children with severe fatty acid oxidation defects. Early diagnosis and treatment may change the natural history of MADD.
Asunto(s)
Acil-CoA Deshidrogenasas/deficiencia , Errores Innatos del Metabolismo de los Aminoácidos/fisiopatología , Carnitina/análogos & derivados , Carnitina/sangre , Dieta , Ácidos Grasos/sangre , Errores Innatos del Metabolismo Lipídico/fisiopatología , Acil-CoA Deshidrogenasa , Errores Innatos del Metabolismo de los Aminoácidos/sangre , Errores Innatos del Metabolismo de los Aminoácidos/dietoterapia , Femenino , Humanos , Recién Nacido , Errores Innatos del Metabolismo Lipídico/sangre , Errores Innatos del Metabolismo Lipídico/dietoterapia , Tamizaje NeonatalRESUMEN
La enfermedad celíaca (EC) provoca un déficit en la absorción de nutrientes, siendo la mala absorción de grasas, una de las primeras manifestaciones. El objetivo de este estudio es describir el patrón de absorción de los distintos ácidos grasos (AG) en niños celíacos con esteatorrea. Se seleccionaron 37 niños con síntomas compatibles con E.C. Fueron instruidos para la realización de una dieta con una distribución de grasas de distinta longitud y grado de saturación: 25 por ciento TCM (triglicéridos de cadena media) y 75 por ciento TCL (triglicéridos de cadena larga; 32 por ciento saturados; 25 por ciento monoinsaturados; 18 por ciento poliinsaturados). El plan alimentario y el registro de consumo fueron realizados durante los 5 días previos a la biopsia intestinal, y en los últimos 3 días se indicó la recolección de todas las deposiciones. Se calculó la ingesta de grasas con diferenciación del tipo de ácido graso. A todos los pacientes se les realizó la biopsia de intestino delgado para confirmar diagnóstico. Se obtuvieron 22 biopsias compatibles con EC, siendo 15 de los niños inclidos en el estudio (12 fem.- 3 masc.), con edades comprendidas entre los 10 m y 5 a 4 m (Me: 25 m). El análisis de los ácidos grasos fecales se efectuó por el método de Lepage y Roy, por cromatografía gas líquido con columna megabore DB-WAX. Los valores se expresaron como Media y Desvió Standard. Los coeficientes de absorción fueron: grasas totales 88.8 por ciento ( más menos 7.3); TCM 99.5 por ciento (más menos 0.7); TCL 84.9 por ciento ( más menos 12.9); A.G. saturados 75 por ciento (más menos 26.5) A.G. monoinsaturados 89.6 por ciento (más menos 14.2); AG poliinsaturados 97.1 por ciento ( más menos 3.9). Los porcentajes de absorción más elevados se encontraron en los TCM y en los A. G. poliinsaturados. La dieta en la E.C debe privilegiar el consumo de las grasas que mostaron ser eficientemente absorbidas.